In the wake of the declaration of a State of National Energy Emergency, the Department of Health has raised significant concerns regarding the potential for a sharp increase in the prices of drugs and medicines. This development follows warnings from international health authorities about the broader implications of global instability on medical supplies.
Monitoring Price Trends and Supply Chain Vulnerabilities
During a recent radio interview, DOH Spokesman Albert Domingo emphasized that the agency aligns with the World Health Organization's assessment. The ongoing Middle East crisis could lead to substantial price spikes for pharmaceuticals and disrupt critical medical supply chains. Domingo stated that while no immediate price hikes have been observed, the situation requires vigilant monitoring due to the reliance of these commodities on logistics, which are susceptible to global disruptions.
Automatic Price Freeze Implementation
With the state of energy emergency now in effect, Domingo clarified that a drug price freeze is automatically activated under existing regulations. This measure applies to all essential medicines listed in the Philippine National Drug Formulary. The DOH interprets the energy emergency as constituting a state of emergency, thereby triggering this protective mechanism without the need for additional orders. The department's primary focus is on closely tracking market prices to ensure compliance and prevent exploitation.
Expanding Protective Measures
Beyond the formulary-covered drugs, the health department is exploring additional strategies to mitigate price increases for other medications. Of particular concern are "innovator drugs," which lack generic alternatives and could experience uncontrolled price hikes. Under the Cheaper Medicines Act, or Republic Act 9502, the President holds the authority to impose maximum retail prices on drugs upon recommendation from the Secretary of Health. Although this power has not yet been exercised, it remains a viable option pending thorough market analysis and official recommendations.
The DOH's proactive stance aims to safeguard public access to affordable medications during this period of uncertainty, ensuring that health care remains accessible despite external economic pressures.
